UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 349

Sortiert nach

Global epidemiology of amyloid light-chain amyloidosis

Orphanet journal of rare diseases, 2022-07, Vol.17 (1), p.1-278, Article 278

2022

Volltextzugriff (PDF)

A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?

Leukemia research, 2024-03, Vol.138, p.107465-107465, Article 107465

2024

Volltextzugriff (PDF)

Targeting the RAS oncogene

Expert opinion on therapeutic targets, 2013-05, Vol.17 (5), p.507-531

2013

Volltextzugriff (PDF)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

Leukemia, 2021-07, Vol.35 (7), p.2119-2124

2021

Volltextzugriff (PDF)

Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes

Haematologica (Roma), 2023-04, Vol.108 (4), p.1196

2023

Volltextzugriff (PDF)

Population Pharmacokinetics and Exposure‐Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies

Journal of clinical pharmacology, 2022-02, Vol.62 (2), p.206-219

2022

Volltextzugriff (PDF)

Response to “Selective PKCδ Inhibitor B106 Elicits Uveal Melanoma Growth Inhibitory Effects Independent of Activated PKC Isoforms”

ACS chemical biology, 2019-01, Vol.14 (1), p.131-131

Faller, Douglas V

2019

Volltextzugriff (PDF)

Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents

Blood, 2012-01, Vol.119 (4), p.1008-1017

2012

Volltextzugriff (PDF)

Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injury

Biochemical pharmacology, 2022-09, Vol.203, p.115168-115168, Article 115168

2022

Volltextzugriff (PDF)

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

Blood, 2018-03, Vol.131 (13), p.1415-1424

2018

Volltextzugriff (PDF)

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

Investigational new drugs, 2022-10, Vol.40 (5), p.1042-1050

2022

Volltextzugriff (PDF)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

Blood advances, 2022-09, Vol.6 (17), p.5132-5145

2022

Volltextzugriff (PDF)

MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression

Cancer letters, 2014-05, Vol.347 (1), p.54-64

2014

Volltextzugriff (PDF)

A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis

Leukemia, 2022-01, Vol.36 (1), p.225-235

2022

Volltextzugriff (PDF)

Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours

British journal of clinical pharmacology, 2019-07, Vol.85 (7), p.1464-1473

2019

Volltextzugriff (PDF)

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

British journal of cancer, 2020-11, Vol.123 (11), p.1590-1598

2020

Volltextzugriff (PDF)

Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States

Leukemia research, 2018-08, Vol.71, p.27-33

2018

Volltextzugriff (PDF)

Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial

Clinical and translational science, 2021-05, Vol.14 (3), p.1069-1081

2021

Volltextzugriff (PDF)

SIRT1 represses estrogen-signaling, ligand-independent ERα-mediated transcription, and cell proliferation in estrogen-responsive breast cells

Journal of endocrinology, 2013-03, Vol.216 (3), p.273-285

2013

Volltextzugriff (PDF)

Pathogenic mitochondrial dysfunction and metabolic abnormalities

Biochemical pharmacology, 2021-11, Vol.193, p.114809-114809, Article 114809

2021

Volltextzugriff (PDF)

Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies

British journal of clinical pharmacology, 2019-11, Vol.85 (11), p.2568-2579

2019

Volltextzugriff (PDF)

Novel Inducers of Fetal Globin Identified through High Throughput Screening (HTS) Are Active In Vivo in Anemic Baboons and Transgenic Mice

PloS one, 2015-12, Vol.10 (12), p.e0144660-e0144660

2015

Volltextzugriff (PDF)

SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells

The Prostate, 2013-04, Vol.73 (5), p.522-530

2013

Volltextzugriff (PDF)

Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

Investigational new drugs, 2021-04, Vol.39 (2), p.488-498

2021

Volltextzugriff (PDF)

Protein kinase C-δ inactivation inhibits the proliferation and survival of cancer stem cells in culture and in vivo

BMC cancer, 2014-02, Vol.14 (1), p.90-90, Article 90

2014

Volltextzugriff (PDF)

1 – 25 von 349

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(331)
Mit Volltextzugriff
(323)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(206)
Life Sciences & Biomedicine
(193)
Humans
(145)
Animals
(93)
Mice
(67)
Biological And Medical Sciences
(61)
Biochemistry & Molecular Biology
(50)
Hematology
(42)
Oncology
(38)
Female
(35)
Fundamental And Applied Biological Sciences. Psychology
(35)
Male
(32)
Cell Line
(31)
Cell Biology
(26)
Medical Sciences
(26)
3t3 Cells
(25)
Pharmacology & Pharmacy
(24)
Adult
(22)
Molecular And Cellular Biology
(22)
Transfection
(22)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Global epidemiology of amyloid light-chain amyloidosis

A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?

Targeting the RAS oncogene

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes

Population Pharmacokinetics and Exposure‐Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies

Response to “Selective PKCδ Inhibitor B106 Elicits Uveal Melanoma Growth Inhibitory Effects Independent of Activated PKC Isoforms”

Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents

Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injury

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression

A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis

Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States

Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial

SIRT1 represses estrogen-signaling, ligand-independent ERα-mediated transcription, and cell proliferation in estrogen-responsive breast cells

Pathogenic mitochondrial dysfunction and metabolic abnormalities

Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies

Novel Inducers of Fetal Globin Identified through High Throughput Screening (HTS) Are Active In Vivo in Anemic Baboons and Transgenic Mice

SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells

Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

Protein kinase C-δ inactivation inhibits the proliferation and survival of cancer stem cells in culture and in vivo

Suchergebnisse filtern